151,587 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by First Turn Management LLC

First Turn Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 151,587 shares of the biotechnology company’s stock, valued at approximately $19,092,000. Ascendis Pharma A/S makes up about 2.7% of First Turn Management LLC’s portfolio, making the stock its 21st biggest position. First Turn Management LLC owned approximately 0.26% of Ascendis Pharma A/S as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Raymond James Financial Services Advisors Inc. increased its position in Ascendis Pharma A/S by 53.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 14,990 shares of the biotechnology company’s stock valued at $1,404,000 after acquiring an additional 5,229 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Ascendis Pharma A/S by 7.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,803 shares of the biotechnology company’s stock worth $1,293,000 after acquiring an additional 921 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Ascendis Pharma A/S by 7.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 6,238 shares of the biotechnology company’s stock valued at $584,000 after acquiring an additional 448 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Ascendis Pharma A/S by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,462 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 714 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Ascendis Pharma A/S by 30.6% during the 3rd quarter. Jennison Associates LLC now owns 159,434 shares of the biotechnology company’s stock worth $14,929,000 after purchasing an additional 37,363 shares during the last quarter.

Analysts Set New Price Targets

ASND has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a research report on Wednesday. Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Citigroup lifted their price target on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, April 22nd. Finally, Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.88.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded down $0.78 on Wednesday, reaching $124.04. 965,451 shares of the company’s stock traded hands, compared to its average volume of 380,539. Ascendis Pharma A/S has a 12 month low of $83.75 and a 12 month high of $161.00. The stock has a 50-day simple moving average of $144.04 and a 200 day simple moving average of $130.25. The stock has a market cap of $7.22 billion, a PE ratio of -12.99 and a beta of 0.54.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.